Trial Profile
Effectiveness of Ustekinumab in Patients Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases in a Real-world Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms TENOR
- Sponsors Janssen-Cilag
- 11 Oct 2023 Status changed from active, no longer recruiting to completed.
- 30 May 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2023 Planned End Date changed from 3 Jul 2023 to 30 Jun 2023.